Pulmonary Pathology
Bahram Nikkhoo; Karim Naseri; Ramyar Rahimi Darehbagh; Mehrdad Habiby; Bahar Moasses-Ghafari
Abstract
BackgroundCovid-19 in known to present with acute respiratory distress syndrome pathological manifestations. Studies have shown that patients with Covid-19 can develope diffuse alveolar damage, acute bronchopneumonia, necrotic bronchiolitis, and viral pneumonia.Case PresentationIn this study, we investigate ...
Read More
BackgroundCovid-19 in known to present with acute respiratory distress syndrome pathological manifestations. Studies have shown that patients with Covid-19 can develope diffuse alveolar damage, acute bronchopneumonia, necrotic bronchiolitis, and viral pneumonia.Case PresentationIn this study, we investigate 11 cases. Needle necropsies of 11 patients, hospitalized at Tohid and Kowsar hospitals of Kurdistan University of medical Sciences, with a positive antemortem SARS-CoV-2 (COVID-19) real time PCR test, were fixated within 3 hours after death in the negative-pressure isolation morgue. The participants included 6 men (54%) and 5 women (46%) with mean age of 73.82 ± 10.58 (52–86) years old. The average hospitalization was 14.27 ± 15.72 days. The results showed an interstitial lymphocytic pneumonitis in most of the cases, with severities ranging from mild to moderate and severe in some cases. In 7 cases, Anthracosis and in one case, anthracosis with fibrosis was evident. Hyaline membrane was reported in two patients. In one case, a severe interstitial lymphocytic pneumonia with intra-alveolar exudate with organization, lithiasis, bronchiolitis pattern (BOOP) along with intra-alveolar hemorrhage and mild fibrosis was seen.ConclusionAs a result, it is suggested to keep an eye on these pathologies in managing severe case of COVID-19 infection.
Pulmonary Pathology
Sotoudeh Mohammadi; Mitra Rezaei; Fatemeh Shojaeian; Mihan Pourabdollah; Leila Mohammadi Ziazi; Sharareh Seifi; Atousa Doroodinia; Babak Salimi; Adnan Khosravi; Mohammad Amin Farhangnasab
Abstract
Background & Objective: Various studies showed the use of epidermal growth factor receptors (EGFRs) gene mutations in the therapeutic plan of patients with advanced lung cancer. This study aimed to investigate the frequency and types of EGFR gene mutations among Iranian patients with lung adenocarcinoma ...
Read More
Background & Objective: Various studies showed the use of epidermal growth factor receptors (EGFRs) gene mutations in the therapeutic plan of patients with advanced lung cancer. This study aimed to investigate the frequency and types of EGFR gene mutations among Iranian patients with lung adenocarcinoma referred to a specialized lung diseases hospital from 2014 to 2019.Methods: The data of all patients with lung adenocarcinoma referred to the Molecular Department of Masih Daneshvari Hospital Laboratory (National Research Institute of Tuberculosis and Lung Diseases) from 2014 to 2019 for EGFR mutation tests were collected. Patients' characteristics data and information on the frequency and types of EGFR gene mutations were obtained from the hospital information system (HIS). The collected data were analyzed using SPSS 25.Results: A total of 570 individuals (Mean age of 58.74, 51.6% Male) were included in the study; 113 out of 570 patients (19.8%) were diagnosed with gene mutation. In terms of the type of mutation, 65 participants (57%) showed deletion, 48 patients (42.1%) were diagnosed with replacement, and one (0.9%) case demonstrated both. Notably, the mutation rate detected among the female patients was significantly higher than the male ones (P=0.001); in particular, deletion type of mutation was found more among women, although both genders were the same in terms of the replacement frequency. However, the age had no effect on the mutation in this study (P=0.05).Conclusion: Among Iranian patients with lung adenocarcinoma, 19.8% harbored EGFR gene mutation. This mutation was found in association with lung cancer and could affect the patient's therapeutic plan.
Pulmonary Pathology
Mohamed Alabiad; Ola Harb; Mohamed Abozaid; Ahmed Embaby; Doaa Mandour; Rehab Hemeda; Amany Shalaby
Abstract
Background and Objective: Diagnosis and discrimination of lung adenocarcinoma (LUAD) from lung squamous cell carcinoma (LUSC) is critical to select the appropriate treatment regimen as recently targeted therapies require accurate subtyping of NSCLCs. There are currently several biomarkers that could ...
Read More
Background and Objective: Diagnosis and discrimination of lung adenocarcinoma (LUAD) from lung squamous cell carcinoma (LUSC) is critical to select the appropriate treatment regimen as recently targeted therapies require accurate subtyping of NSCLCs. There are currently several biomarkers that could be used for differentiation between LUAD and LUSC, but they have less sensitivity, specificity, and clinical applicability. The aimof this study was to assess the diagnostic and prognostic values of CLCA2, SPATS2, ST6GALNAC1, and Adipophilin tissue expression in the tissues retrieved from LUAD and LUSC patients using immunohistochemistry. Methods:The current study was performed on the samples retrieved from sixty primary lung masses that were diagnosed as LUAD and LUSC. Immunohistochemistry was performed by using a panel of CLCA2, SPATS2, and ST6GALNAC1. We assessed the diagnostic roles of the studied markers in the discrimination between LUAD and LUSC and their prognostic values. Results: SPATS2 and CLCA2were expressed more in LUSC than LUAD. ST6GALNAC1 and Adipophilin were expressed more in LUAD than LUSC (p <0.001). The sensitivity and specificity of CLCA2, SPATS2, ST6GALNAC1 and Adipophilin in adequate subtyping and reaching the accurate diagnosis was 100%. We found only significant differences in survival rates between the patients with negative and positive CLCA2expression (p =0.038 and p =0.019, respectively). Conclusions: The combination of CLCA2, SPATS2, ST6GALNAC1, and Adipophilin lead to the adequate subtyping of lung cancer and reaching accurate diagnosis with the highest sensitivity and specificity.
